<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617695</url>
  </required_header>
  <id_info>
    <org_study_id>D1221C00005</org_study_id>
    <nct_id>NCT00617695</nct_id>
  </id_info>
  <brief_title>Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study With Single-Blind, Placebo-Challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig)
      nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a
      3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache response and pain-free response to treatment</measure>
    <time_frame>15 minutes, 30 minutes, 45 minutes, 1.5 hours and 2 hours after randomized treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event reports</measure>
    <time_frame>Four times within 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>5mg nasal spray</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zomig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents aged 12-17 years at the time of screening. Patients must not be enrolled
             if they will turn 18 years of age within 12 weeks after randomization.

          -  An established diagnosis of migraine for at least 1 year; a minimum of 2 migraines,
             considered to be moderately/severely disabling, per month on average during the school
             year

          -  A history of usual migraine duration of &gt;2-hours untreated for the 3 month prior to
             screening

        Exclusion Criteria:

          -  A history of basilar, ophthalmoplegic or hemiplegic migraine headache or any
             potentially serious neurological condition that is associated with headache or
             clinically significant abnormalities indicated from the medical history, physical exam
             etc

          -  Has used monoamine oxidase inhibitor-A (MAO-A), methysergide, methylergonovine or
             cimetidine in the 2 weeks before randomization.

          -  Evidence of ischemic heart disease, arrhythmia, accessory conduction pathway disorder
             as determined by central cardiologist using predetermined and agreed upon pediatric
             standards; Has uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <keyword>Zolmitriptan</keyword>
  <keyword>ZOMIG</keyword>
  <keyword>migraine</keyword>
  <keyword>headache response</keyword>
  <keyword>headache</keyword>
  <keyword>headache pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

